Alirocumab Market Report 2026

The alirocumab market size has grown rapidly in recent years. It will grow from $2.1 billion in 2025 to $2.32 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to rising ldl cholesterol prevalence, increasing cardiovascular disease burden, statin therapy limitations, early biologics adoption in lipid management, clinical guideline advancements in hypercholesterolemia.

The alirocumab market size is expected to see rapid growth in the next few years. It will grow to $3.48 billion by 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to aging global population growth, expansion of pcsk9 inhibitor pipeline, increasing reimbursement coverage for biologics, growth in home-based self-administration therapies, expansion of cardiovascular preventive care programs. Major trends in the forecast period include increasing adoption of pcsk9 inhibitor therapies, rising prevalence of statin intolerance patients, expansion of cardiovascular risk screening programs, growth in monoclonal antibody-based lipid lowering therapies, rising demand for combination lipid lowering regimens.

The growing incidence of cardiovascular diseases is anticipated to propel the expansion of the alirocumab market in the coming years. Cardiovascular diseases represent a cluster of disorders impacting the heart and blood vessels, encompassing conditions such as coronary artery disease, cerebrovascular disease, and heart failure, which together hinder the effective circulation of blood and oxygen throughout the body. A major contributor to the rising incidence of cardiovascular diseases is the widespread prevalence of sedentary lifestyles, as limited physical activity leads to metabolic imbalance, encourages excessive fat accumulation, and speeds up the emergence of risk factors such as hypertension and dyslipidemia, thereby substantially increasing the probability of cardiovascular complications over time. Alirocumab works by reducing low-density lipoprotein cholesterol levels through the inhibition of proprotein convertase subtilisin/kexin type 9, thereby assisting in lowering cardiovascular risk and managing disease progression in populations increasingly impacted by these conditions. For example, in June 2024, according to data released by the American Heart Association Inc., a US-based non-profit organization, cardiovascular disease prevalence in the United States is expected to increase from around 50% of adults currently to 61% by 2050. Therefore, the growing incidence of cardiovascular diseases is driving the expansion of the alirocumab market.

Leading companies operating in the alirocumab market are focusing on developing innovative products, such as expanded indication biologics to broaden patient eligibility and enhance early-stage disease management. An expanded indication biologic is a therapeutic agent that receives regulatory approval for use in additional patient populations or disease conditions beyond its original indication. For example, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, announced U. S. Food and Drug Administration approval for Praluent. This development extends the use of alirocumab to pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia, enabling earlier intervention in genetically predisposed individuals. The approval strengthens preventive cardiovascular care by improving low-density lipoprotein cholesterol management and expanding the therapy’s clinical and commercial scope.

The increasing adoption of personalized medicine strategies is anticipated to fuel the growth of the alirocumab market in the future due to the rising need for targeted therapies that enable accurate treatment and improved cardiovascular risk management outcomes. Personalized medicine refers to a healthcare approach that customizes treatment plans based on individual patient characteristics, including genetic makeup, biomarker information, lifestyle factors, and disease-specific attributes, with the aim of enhancing treatment effectiveness and reducing adverse effects. A key driver behind the growing adoption of personalized medicine is the expanding integration of genomic data into clinical practice, as advances in genetic profiling allow healthcare providers to more accurately identify disease risks and treatment responses, thereby enabling more precise and effective therapeutic decisions. Alirocumab contributes to personalized medicine by providing a targeted lipid-lowering treatment particularly useful for patients with genetic lipid disorders or those who do not respond adequately to standard therapies, thereby improving individualized cardiovascular risk management. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, more than one-third of all new drug approvals by the U. S. Food and Drug Administration have consistently been personalized therapies for four consecutive years through 2023, with 2023 approvals including 16 rare disease treatments (compared to six in 2022), along with seven oncology drugs and three therapies for other conditions. Therefore, the increasing adoption of personalized medicine strategies is driving the growth of the alirocumab market.

Major companies operating in the alirocumab market are Sanofi S. A., Regeneron Pharmaceuticals Inc.

North America was the dominating region in the alirocumab market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the alirocumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the alirocumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alirocumab market consists of sales of anticoagulants, blood-thinning medications, anti-hypertensive drugs, and high-dose ophthalmology biologics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.